金地商置(00535.HK)：中期股东应占亏损为10.08亿元 金地商置(00535.HK)拟8月22日举行董事会会议以 审批中期业绩 相关事件 格隆汇8月22日丨金地商置(00535.HK)发布公告，截至2025年6月30日止六个月，实现收入人民币64.68 亿元，同比增加97%；毛利为人民币9.31亿元，同比增加67%；公司持有人应占亏损为人民币10.08亿 元，上年同期公司持有人应占亏损为人民币21.79亿元；基本每股亏损人民币0.0607元。 报告期内，物业发展分部收入为人民币58.37亿元，占总收入90%，相对截至2024年6月30日止相应期的 收入则为人民币26.33亿元，占总收入的80%。分部收入增加主要是本期销售物业交付的面积增加所 致。本期间的分部业绩录得亏损人民币6.86亿元，较上年相应期的分部亏损人民币20.17亿元减少人民币 13.31亿元。本期的分部亏损主要因若干联合营公司的物业存货有大额减值拨备，就此对应收该等联合 营公司款项计提减值人民币7.33亿元。而上年相应期的分部亏损主要是就附属公司及合营公司持有的若 干物业存货进行大额减值拨备。 ...

期内收入同比增加，主要因本期间物业销售的收入确认增加所致。 金地商置(00535)发布截至2025年6月30日止六个月业绩，收入64.68亿元(人民币，下同)，同比增长97%; 公司持有人应占亏损10.08亿元，同比收窄54%;每股基本亏损0.0607元。 ...

期内收入同比增加，主要因本期间物业销售的收入确认增加所致。 智通财经APP讯，金地商置(00535)发布截至2025年6月30日止六个月业绩，收入 64.68亿元(人民币，下 同)，同比增长97%;公司持有人应占亏损 10.08亿元，同比收窄54%;每股基本亏损0.0607元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因依賴該等內容而引致之任何 損失承擔任何責任。 金地商置集團有限公司* （於百慕達註冊成立之有限公司） （股份代號：535） 截至2025年6月30日止六個月之 未經審核中期業績公佈 財務概要 | | 截至 6 | 月 30 日止六個月 | | | | | --- | --- | --- | --- | --- | --- | | | 2025 年 | 2024 | 年 | | 變動 | | | ⼈⺠幣千元 | ⼈⺠幣千元 | | | % | | | (未經審核) | (未經審核) | | | | | 收入 | 6,467,765 | 3,286,864 | | ＋ | 97 | | 毛利 | 931,231 | 557,414 | | ＋ | 67 | | 其他收入及收益 | 195,699 | 354,290 | | － | 45 | | 應佔合營公司及聯營公司業績 | (128,188) | (1,362,678) | | － | 91 | | ...

[Supplementary Announcement Regarding the 2024 Annual Report](index=1&type=section&id=Supplementary%20Announcement%20regarding%20the%202024%20Annual%20Report) [Purpose and Background of the Announcement](index=1&type=section&id=Purpose%20and%20Background%20of%20the%20Announcement) This announcement provides supplementary information on continuing connected transactions disclosed in Gemdale Properties and Investment Corporation Limited's 2024 annual report, in accordance with Hong Kong Listing Rules 14A.71(2) and (5) - This announcement supplements Gemdale Properties and Investment Corporation Limited's 2024 annual report, primarily providing additional information on continuing connected transactions[3](index=3&type=chunk) - The supplement is based on Listing Rules 14A.71(2) and (5)[3](index=3&type=chunk) [Details of Continuing Connected Transactions](index=1&type=section&id=Details%20of%20Continuing%20Connected%20Transactions) The company entered into a three-year Shanghai Xinhua Road Lease Framework Agreement with Shanghai Jincheng, a subsidiary of its ultimate controlling shareholder, to lease properties on Shanghai Xinhua Road, effective January 1, 2024 [Parties and Nature of the Transaction](index=1&type=section&id=Parties%20and%20Nature%20of%20the%20Transaction) - The parties involved are Shanghai Jincheng (as landlord) and the Company, its subsidiaries, and/or its associates (as tenants)[3](index=3&type=chunk) - The transaction involves the lease of certain properties located on Shanghai Xinhua Road[3](index=3&type=chunk) - The lease term is **3 years**, effective from January 1, 2024[3](index=3&type=chunk) [Relationship of Connected Parties](index=1&type=section&id=Relationship%20of%20Connected%20Parties) - Shanghai Jincheng is a subsidiary of Gemdale Corporation, which is the ultimate controlling shareholder of the Company[3](index=3&type=chunk) - Under the Listing Rules, Shanghai Jincheng is identified as a connected person of the Company, making this lease agreement a continuing connected transaction[3](index=3&type=chunk) [Impact on the 2024 Annual Report](index=1&type=section&id=Impact%20on%20the%202024%20Annual%20Report) This supplementary information does not affect other details within the 2024 annual report, with the remaining content unchanged - This supplementary information does not impact other data in the 2024 annual report[3](index=3&type=chunk) - Except for the content disclosed in this announcement, the remaining content of the 2024 annual report remains unchanged[3](index=3&type=chunk) [Board of Directors Information](index=1&type=section&id=Board%20of%20Directors%20Information) - As of August 22, 2025, the Board of Directors comprises **four Executive Directors**, **two Non-executive Directors**, and **three Independent Non-executive Directors**[5](index=5&type=chunk) - Executive Directors include Mr Huang Juncan, Mr Xu Jiajun, Mr Li Ronghui, and Mr Wei Chuanjun[5](index=5&type=chunk) - Non-executive Directors include Mr Loh Lian Huat and Ms Zhang Feiyun[5](index=5&type=chunk) - Independent Non-executive Directors include Mr Hui Chiu Chung, Mr Jiang Shangyi, and Mr Xia Xinping[5](index=5&type=chunk)

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因依賴該等 內容 而引致的任何損失承擔任何責任。 Gemdale Properties and Investment Corporation Limited 金地商置集團有限公司* （於百慕達註冊成立之有限公司） （股份代號：535） 根據上市規則 第13.51(2)(l)條及第13.51B(2)條作出 的董事資料更新 本公告乃金地商置集團有限公司（「本公司」，連同其附屬公司，統稱「本集團」）根 據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.51(2)(l) 條及第13.51B(2)條而作出，內容關於本公司獨立非執行董事許照中先生（「許先生」） 的資料更新。 本公司董事會（「董事會」）接獲許先生通知，指彼近期知悉香港高等法院於2025年8月 11日對華南城控股有限公司（「華南城」，許先生當時擔任該公司獨立非執行董事）頒 佈清盤命令（「清盤令」），且華南城的臨時清盤人已獲香港高等法院委任。許先生於 2011年4月11日獲委任為 ...

Group 1 - The company, Gemdale Corporation (00535.HK), announced a board meeting scheduled for August 22, 2025, to consider and approve its unaudited interim results for the six months ending June 30, 2025 [1] - The meeting will also address any other matters that may arise [1]

金地商置集團有限公司（「本公司」）董事會（「董事會」）謹此宣佈將於2025年8 月22日舉行董事會會議，以考慮及批准（其中包括）本公司及其附屬公司截至2025 年6月30日止六個月之未經審核中期業績及其發佈，以及處理任何其他事項（如 有）。 承董事會命 金地商置集團有限公司 執行董事 徐家俊 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 Gemdale Properties and Investment Corporation Limited 金地商置集團有限公司* （於百慕達註冊成立之有限公司） （股份代號：535） 董事會會議通告 香港，2025年8月12日 於本公佈日期，董事會成員包括四名執行董事黃俊燦先生、徐家俊先生、李榮輝先生及韋傳軍先 生；兩名非執行董事 Loh Lian Huat 先生及張斐贇女士；以及三名獨立非執行董事許照中先生、 蔣尚義先生及夏新平先生。 * 僅供識別 C:\C S\Quarterly Results\1Q-07-0 ...

Performance Highlights - BeiGene (06160.HK) reported a revenue of 17.518 billion yuan for the first half of the year, a year-on-year increase of 46%; product revenue was 17.36 billion yuan, up 45.8%; net profit was 450 million yuan, turning from loss to profit [2] - Uni-President China (00220.HK) achieved approximately 17.087 billion yuan in revenue for the first half, a year-on-year increase of 10.6%; net profit was about 1.287 billion yuan, up 33.2% [2] - Zhiyu City Technology (09911.HK) announced a positive profit forecast, expecting mid-term revenue of approximately 3.135 to 3.215 billion yuan, a year-on-year increase of about 38.0% to 41.5%; net profit is expected to be around 470 to 510 million yuan, a year-on-year growth of approximately 108.9% to 126.7% [2] Earnings Forecasts - New World Development Company (00086.HK) expects mid-term net profit to increase to no less than 800 million HKD year-on-year [3] - Weizhi Jinkou (02003.HK) anticipates mid-term net profit exceeding 200 million HKD, a significant increase year-on-year [3] - Wing Chan Industrial (01596.HK) forecasts mid-term net profit of approximately 48.7 million HKD, turning from loss to profit [3] - Huaxian Optoelectronics (00334.HK) expects mid-term net profit to exceed 48.8 million HKD, a year-on-year increase of over 600% [3] - Maifushi (02556.HK) predicts mid-term net profit of approximately 31.8 to 41 million HKD, turning from loss to profit [4] - Xinwei Medical-B (06609.HK) expects mid-term net profit to exceed 40 million HKD, turning from loss to profit [5] - China Nuclear Technology (00611.HK) anticipates mid-term net profit growth of over 15% [6] Earnings Warnings - Hongxing Printing Group (00450.HK) expects mid-term net loss of approximately 49 million HKD, a significant increase year-on-year [7] - Zhongyu Land (01224.HK) forecasts mid-term net loss of approximately 40 million HKD, turning from profit to loss [7] - Beihai Group (00701.HK) anticipates mid-term net loss of 36 to 40 million HKD [8] Real Estate Sales Data - China Overseas Development (00688.HK) reported cumulative contract property sales of approximately 132 billion yuan for the first seven months, a year-on-year decrease of 18.3% [9] - Yuexiu Property (00123.HK) achieved cumulative contract sales of approximately 67.506 billion yuan for the first seven months, a year-on-year increase of about 11.7% [9] - Poly Property Group (00119.HK) reported contract sales of approximately 29.5 billion yuan for the first seven months, a year-on-year decrease of 13.49% [10] - China Overseas Hongyang Group (00081.HK) reported cumulative contract sales of 18.649 billion yuan for the first seven months, a year-on-year decrease of 12.2% [10] - Jindi Commercial Real Estate (00535.HK) reported cumulative contract sales of approximately 6.98 billion yuan for the first seven months, a year-on-year decrease of 37.37% [10] - Agile Group (03383.HK) reported pre-sale amount of approximately 5.69 billion yuan for the first seven months [11] - Hongyang Real Estate (01996.HK) reported cumulative contract sales of 3.208 billion yuan for the first seven months, a year-on-year decrease of 41.6% [12] - Zhengrong Real Estate (06158.HK) reported cumulative contract sales of approximately 2.701 billion yuan for the first seven months, a year-on-year decrease of 30.6% [12] - Jingrui Holdings (01862.HK) reported cumulative contract sales of approximately 571 million yuan for the first seven months, a year-on-year decrease of 52.54% [13] Company News - CITIC Securities (06030.HK) reported that its subsidiary, Huaxia Fund, achieved revenue of 4.258 billion yuan and net profit of 1.123 billion yuan in the first half, with assets under management totaling 285.1237 billion yuan [14] - Xinyi International (00732.HK) reported a cumulative operating revenue of approximately 9.566 billion HKD for the first seven months, a year-on-year decrease of about 5.3% [15] - Heng Rui Pharmaceutical (01276.HK) received orphan drug designation from the US FDA for its injection of Rikan Trastuzumab combined with Adebali for gastric cancer or gastroesophageal junction adenocarcinoma indications [15] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® for active renal glomerulonephritis in China [15] - China Biopharmaceutical (01177.HK) announced that its self-developed TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program for the treatment of chronic graft-versus-host disease [15] Buyback Activities - HSBC Holdings (00005.HK) repurchased approximately 1.65 billion HKD worth of about 1.714 million shares at a price of 95.8 to 96.75 HKD [16] - Hang Seng Bank (00011.HK) spent approximately 22.6347 million HKD to repurchase 200,000 shares at a price of 112.8 to 113.6 HKD [17] - Yum China (09987.HK) repurchased approximately 6.264 million HKD worth of 16,800 shares at a price of 369.8 to 376 HKD [17]

Core Viewpoint - The company reported its contract sales figures for July 2025, indicating a total contract sales amount of approximately RMB 1.28 billion and a sales area of about 90,400 square meters, with an average selling price of around RMB 14,200 per square meter [1] Summary by Relevant Sections - **Contract Sales for July 2025** - The total contract sales amount for July 2025 was approximately RMB 1.28 billion [1] - The total sales area for the same period was about 90,400 square meters [1] - The average selling price during this period was around RMB 14,200 per square meter [1] - **Cumulative Contract Sales from January to July 2025** - The cumulative contract sales amount from January to July 2025 reached approximately RMB 6.98 billion [1] - The cumulative sales area for this period was about 542,700 square meters [1]